US patient advocacy groups received majority of pharma donations in multi-country study

February 22, 2019

A new study by Johns Hopkins Bloomberg School of Public Health researchers found that U.S.-based patient advocacy organizations received a disproportionate amount of contributions made by the world's 10 largest pharmaceutical companies in 2016.

The study assessed contributions to patient advocacy groups in seven countries and the United Kingdom and found that U.S.-based patient advocacy organizations received 74 percent of total contributions in 2016, or an estimated $88 million dollars.

Patient advocacy organizations are nonprofit groups that focus on specific medical conditions. They are found in almost every industrialized country and seek to raise awareness, lobby for research and treatment options as well as provide patient and caregiver education, advocacy and support services.

The study was published online February 21, 2019 in the American Journal of Public Health.

"Patient advocacy groups have an important role when they testify in Congress, at the Food and Drug Administration, the Centers for Medicare & Medicaid Services and other government agencies," says senior co-author Gerard Anderson, PhD, professor in the Bloomberg School's Department of Health Policy and Management. "It is important for policymakers to understand the funding sources for these organizations."

The report reveals a patchwork of disclosure levels among countries, with only six of the 10 drug companies disclosing their financial donations to U.S.-based patient advocacy organizations in 2016. This disclosure gap suggests that the total amount of contributions to U.S.-based patient groups was even higher, as four companies did not disclose their U.S. contributions.

In contrast, the study found that all 10 companies disclosed their 2016 financial transactions to patient advocacy organizations in France, Germany and the United Kingdom, which encourage or require such disclosure.

The authors say the findings underscore the importance of transparency given the growing role of patient advocacy groups, particularly in the U.S., and recommend moving to greater disclosure, either voluntary or regulatory.

"Patient advocacy groups have grown exponentially in the last 10 years, but the magnitude of pharmaceutical industry funding to them across countries has not been measured before," says So-Yeon Kang, MPH, MBA, lead study author and research associate in the Bloomberg School's Department of Health Policy and Management. "Patient advocacy organizations are supposed to represent their constituents' interests. Transparency is critical to avoid conflict of interests."

For their study, the researchers identified the world's 10 largest pharmaceutical companies based on total global revenue in 2016: Pfizer, Novartis, Roche, Sanofi, Merck, AbbVie, Amgen, Gilead, Janssen and GlaxoSmithKline. Together they accounted for 41 percent of pharmaceutical industry revenue that year. The study authors then researched disclosures for contributions from these 10 companies to patient advocacy groups based in Canada, France, Germany, Italy, Japan, Spain, the United Kingdom and the U.S. The researchers collected financial information from pharmaceutical websites, funding reports and other public-facing documentation, such as annual reports.

In France, Germany and the United Kingdom, where all 10 pharmaceutical companies disclosed financial contributions to patient groups, the researchers note that in addition to robust regulatory frameworks, information about disclosures was easily accessible and content was consistent.

Other countries, including the United States, had varying amounts of disclosed information available. The researchers report that they encountered several barriers with data collection in the U.S., including different reporting styles and mixed information with various types of grants.

The six companies that disclosed contributions to U.S. groups contributed $120 million in patient advocacy funding to the study countries--$88 million to U.S. groups and $32 million to groups in the remaining six countries and the U.K.

Researchers also wanted to understand the relationship between patient advocacy groups and the pharmaceutical market in the respective countries. The researchers did not find any association between companies' contributions to a country's patient advocacy groups and the country's population, pharmaceutical revenue or GDP.

"If financial support to patient advocacy organizations is really about patient education, you would expect the funding to be the same in each country," says Anderson. "This analysis shows that there's no correlation and something more than patient education influences the level of patient advocacy organization support in a country."

The disproportionate amount of funding to U.S. patient advocacy organizations and unregulated financial disclosures highlight the importance of establishing reporting guidelines.

"Legislative actions, such as expanding the Physician Payment Sunshine Act, would insure universal disclosure compliance," says Kang. "But as an intermediary step, the industry should consider adopting a voluntary disclosure requirement at the trade association level. They already have it in Europe. Why not in the U.S.?"

Increased transparency, the authors say, would help address potential conflicts of interest associated with the pharmaceutical industry's support. "The U.S. has one of the most robust drug regulation processes," explains Anderson. "It is often the first country to adopt prescription drugs and therefore has a significant influence on a product's performance in a global market. Regulation is important because these groups can be influenced by the money they receive from drug companies."
-end-
This study was supported by the Laura and John Arnold Foundation.

"Pharmaceutical Companies Support US Patient-Advocacy Organizations: An International Context" was written by So-Yeon Kang, MPH, MBA, Ge Bai, PhD, CPA, Laura Karas, MD, MPH, and Gerard F. Anderson, PhD.

Johns Hopkins University Bloomberg School of Public Health

Related Public Health Articles from Brightsurf:

COVID-19 and the decolonization of Indigenous public health
Indigenous self-determination, leadership and knowledge have helped protect Indigenous communities in Canada during the coronavirus disease 2019 (COVID-19) pandemic, and these principles should be incorporated into public health in future, argue the authors of a commentary in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.200852.

Public health consequences of policing homelessness
In a new study examining homelessness, researchers find that policy such a lifestyle has massive public health implications, making sleeping on the street even MORE unhealthy.

Electronic health information exchange improves public health disease reporting
Disease tracking is an important area of focus for health departments in the midst of the COVID-19 pandemic.

Pandemic likely to cause long-term health problems, Yale School of Public Health finds
The coronavirus pandemic's life-altering effects are likely to result in lasting physical and mental health consequences for many people--particularly those from vulnerable populations--a new study led by the Yale School of Public Health finds.

The Lancet Public Health: US modelling study estimates impact of school closures for COVID-19 on US health-care workforce and associated mortality
US policymakers considering physical distancing measures to slow the spread of COVID-19 face a difficult trade-off between closing schools to reduce transmission and new cases, and potential health-care worker absenteeism due to additional childcare needs that could ultimately increase mortality from COVID-19, according to new modelling research published in The Lancet Public Health journal.

The Lancet Public Health: Access to identification documents reflecting gender identity may improve trans mental health
Results from a survey of over 20,000 American trans adults suggest that having access to identification documents which reflect their identified gender helps to improve their mental health and may reduce suicidal thoughts, according to a study published in The Lancet Public Health journal.

The Lancet Public Health: Study estimates mental health impact of welfare reform, Universal Credit, in Great Britain
The 2013 Universal Credit welfare reform appears to have led to an increase in the prevalence of psychological distress among unemployed recipients, according to a nationally representative study following more than 52,000 working-age individuals from England, Wales, and Scotland over nine years between 2009-2018, published as part of an issue of The Lancet Public Health journal on income and health.

BU researchers: Pornography is not a 'public health crisis'
Researchers from the Boston University School of Public Health (BUSPH) have written an editorial in the American Journal of Public Health special February issue arguing against the claim that pornography is a public health crisis, and explaining why such a claim actually endangers the health of the public.

The Lancet Public Health: Ageism linked to poorer health in older people in England
Ageism may be linked with poorer health in older people in England, according to an observational study of over 7,500 people aged over 50 published in The Lancet Public Health journal.

Study: Public transportation use linked to better public health
Promoting robust public transportation systems may come with a bonus for public health -- lower obesity rates.

Read More: Public Health News and Public Health Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.